Characterization and management of adverse reactions (ARs) in patients with advanced renal cell carcinoma (aRCC) receiving lenvatinib plus pembrolizumab (CLEAR study) Meeting Abstract
| Authors: | Motzer, R.; George, S.; Merchan, J. R.; Hutson, T. E.; Song, X.; Perini, R. F.; Xie, R.; Bapat, U.; Ebaid, B.; Puente, J. |
| Abstract Title: | Characterization and management of adverse reactions (ARs) in patients with advanced renal cell carcinoma (aRCC) receiving lenvatinib plus pembrolizumab (CLEAR study) |
| Meeting Title: | 49th Annual Scientific Meeting of the Clinical Oncology Society of Australia (COSA) |
| Journal Title: | Asia-Pacific Journal of Clinical Oncology |
| Volume: | 18 |
| Issue: | Suppl. 3 |
| Meeting Dates: | 2022 Nov 2-4 |
| Meeting Location: | Brisbane, QLD, Australia |
| ISSN: | 1743-7555 |
| Publisher: | Wiley Blackwell |
| Date Published: | 2022-11-01 |
| Start Page: | 121 |
| End Page: | 122 |
| Language: | English |
| ACCESSION: | WOS:000871956500169 |
| PROVIDER: | wos |
| DOI: | 10.1111/ajco.13869 |
| Notes: | Meeting Abstract: 196 -- This meeting abstract was published under the "Poster Abstracts" section of the issue -- Source: Wos |
